Community/Retail

Officials with the FDA have approved an Alkermes aripiprazole lauroxil (Aristada Initio) extended-release product for the treatment of schizophrenia in adults, according to the company.

The FDA voted against recommendign oxycodone extended-release capsules (REMOXY ER, Pain Therapeutics) for approval for the management of pain severe enough to require long-term, around-the-clock opioid treatment, during a joint meeting of the agency’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC), and the Drug Safety and Risk Management Advisory Committee (DSARM).